{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-015054","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2025-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.814281+00:00","generated_at":"2026-05-17T05:32:52.982789+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harrow signs definitive deal to acquire Melt Pharma for initial $4.3M plus milestones up to ~$352.5M","bullets":["Initial cash payment of ~$4.3M for remaining 55% equity; contingent $87.2M upon FDA approval of MELT-300.","Upon CMS J-Code assignment, Harrow will issue ~1.112M shares of common stock.","Additional cash payments up to ~$261M based on annual net sales milestones ($100M–$1B).","Harrow plans NDA submission in 2027, potential US launch in 2028 for MELT-300 sublingual sedation.","Deal approved by independent committee; fairness opinion from Lake Street Capital Markets."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-015054","json":"https://secwatch.observer/filing/0001493152-25-015054.json","markdown":"https://secwatch.observer/filing/0001493152-25-015054.md","text":"https://secwatch.observer/filing/0001493152-25-015054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000149315225015054/0001493152-25-015054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000149315225015054/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:32:52.982789+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}